Published by Josh White on 4th September 2025
(Sharecast News) - Shield Therapeutics said on Thursday that the US Food and Drug Administration (FDA) has granted priority review to extend the indication of its oral iron therapy Accrufer/Feraccru to adolescents aged 10 and above, with potential approval expected in 2026.